A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant

University of Minnesota115 enrolled

Overview

RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works compared with standard therapy in cancer patients undergoing a donor bone marrow transplant.

OBJECTIVES: Primary * Compare the effects of a structured walking regimen vs normal standard care on functional status at day 100 after allogeneic bone marrow transplantation in patients with cancer. Secondary * Compare the effects of these regimens on patient survival at day 100 and at 1 year after transplantation. * Compare patient satisfaction with these regimens. OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 intervention arms. * Arm I: Beginning 2-3 days after allogeneic bone marrow transplantation, patients walk on a treadmill or in the hospital hallways twice daily for ≥ 15 minutes. After discharge and continuing for up to 100 days post-transplantation, patients walk once daily for ≥ 30 minutes. Patients record their walking times daily in a journal. * Arm II: Patients receive no special instructions regarding exercise other than the normal standard of care. All patients complete questionnaires at discharge and at day 100 post-transplantation measuring daily exercise activities, satisfaction with the recommended walking regimen, and functional status. PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Enrollment

115

Conditions

Cancer

Interventions

exercise interventionBEHAVIORAL

management of therapy complicationsPROCEDURE

observationPROCEDURE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following malignancies: * Acute lymphocytic leukemia * Chronic myelogenous leukemia * Acute myeloid leukemia * Hodgkin's lymphoma * Non-Hodgkin's lymphoma * Myelodysplastic syndromes * Other malignancy * Undergoing concurrent allogeneic bone marrow transplantation PATIENT CHARACTERISTICS: * Able to walk PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Outcomes

Primary Outcomes

Difference in functional status as measured by Karnofsky performance scores at day 0 of allogeneic bone marrow transplantation and at day 100 post-transplantation

Secondary Outcomes

Survival at day 100 and at 1 year post-transplantation

Patient satisfaction with the suggested exercise regimen as measured by the Wilcoxon test using a 5-point rating scale

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.